PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:

(11) International Publication Number:

WO 00/34240

C07D 205/08

(43) International Publication Date:

15 June 2000 (15.06.00)

(21) International Application Number:

PCT/US99/27914

A1

(22) International Filing Date:

6 December 1999 (06.12.99)

(30) Priority Data:

09/206.931

7 December 1998 (07.12.98)

US

- (71) Applicant: SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).
- (72) Inventors: THIRUVENGADAM, Tiruvettipuram, K.; 17 Village Road, Kendall Park, NJ 08824 (US). FU, Xiaoyong; 18 Augusta Avenue, Edison, NJ 08820 (US). TANN, Chou-Hong; 30 Pinewood Crescent, Berkeley Heights, NJ 07922 (US). McALLISTER, Timothy, L.; Apartment 3L, 1 Primrose Lane, Fords, NJ 08863 (US). CHIU, John, S.; 12 Ferndale Drive, Parsippany, NJ 07054 (US). COLON, Cesar, 849 Apgar Terrace, Rahway, NJ 07065 (US).
- (74) Agents: MAGATTI, Anita, W. et al.; Schering-Plough Corporation, Patent Dept., K-6-1 1990, 2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PROCESS FOR THE SYNTHESIS OF AZETIDINONES

(57) Abstract

This invention provides a process for preparing the hypocholesterolemic compound (I) comprising: (a) reacting p-fluorobenzoylbutyric acid with pivaloyl chloride and acylating the product with a chiral auxiliary to obtain a ketone of formula (IV); (b) reducing the ketone of formula (IV) in the presence of a chiral catalyst to an alcohol; (c) reacting the chiral alcohol of step (b), an imine and a silyl protecting agent, then condensing the protected compounds to obtain a β -(substituted-amino)amide of formula (VII); (d) cyclizing the β-(substituted-amino)amide of formula (VII) with a silylating agent and a fluoride ion catalyst to obtain a protected lactam of formula (VIII); and removing the protecting groups. The intermediates of formulas (VII and VIII) are also claimed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM Armenia FI Finland LT Lithuania SK Slovakia AT Austria FR France LU Luxembourg SN Senegal AU Australia GA Gabon LV Lurvia SZ Swaziland AZ Azerbaijan GB United Kingdom MC Monaco TD Chad BA Boania and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkcy BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CC Caneron Republic of Korea PL Poland CC Caneron Republic of Korea PL Poland CC Cated Twoire KP Democratic People's NZ New Zealand CC Cated Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan EE Estonia LR Liberia SG Singapore	AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AU Australia GA Gabon LV Laivia SZ Swaziland AZ Azerbaijan GB United Kingdom MC Monaco TD Chad BA Boania and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CN China KR Republic of Korea PI Poland CC Cotea Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AZ Azerbaijan GB United Kingdom MC Monaco TD Chad BA Bonia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkcy BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolis UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BBY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PL Poland CC Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
BA Bosnia and Herzegovina GE Georgia MD Republic of Moldova TG Togo BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CM Cameroon Republic of Korea PL Poland CM Cameroon Republic of Korea PL Poland CC Cuba KZ Kazakstan RO Romania CC Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
BB Barbados GH Ghana MG Madagascar TJ Tajikistan BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CC Cuba KZ Kazakstan RO Romania CC Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BE Belgium GN Guinea MK The former Yugoslav TM Turkmenistan BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Cote d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CCN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakatan RO Romania CCZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BF Burkina Faso GR Greece Republic of Macedonia TR Turkey BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CCN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CCZ Czech Republic CZ Czech Republic CL Saim Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BB	Barbados	GH	Ghana	MG	Madagascar	ŢJ	Tajikistan
BG Bulgaria HU Hungary ML Mali TT Trinidad and Tobago BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CC Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BJ Benin IE Ireland MN Mongolia UA Ukraine BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BR Brazil IL Israel MR Mauritania UG Uganda BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saimt Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BY Belarus IS Iceland MW Malawi US United States of America CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CCZ Czech Republic LC Saim Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BJ	Benin	IE	Ireland	MN	Mangolia	UA	Ukraine
CA Canada IT Italy MX Mexico UZ Uzbekistan CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CC Czech Republic LC Saim Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
CF Central African Republic JP Japan NE Niger VN Viet Nam CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Cte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CG Congo KE Kenya NL Netherlands YU Yugoslavia CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	CA	Canada	ΙT	Italy	MX	Mexico	UZ	Uzbekistan
CH Switzerland KG Kyrgyzstan NO Norway ZW Zimbabwe CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CI Côte d'Ivoire KP Democratic People's NZ New Zealand CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saimt Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CM Cameroon Republic of Korea PL Poland CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	СН	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CN China KR Republic of Korea PT Portugal CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CU Cuba KZ Kazakstan RO Romania CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	CM	Cameroon		Republic of Korea	PL	Poland		
CZ Czech Republic LC Saint Lucia RU Russian Federation DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	CN	China	KR	Republic of Korea	PT	Portugal		
DE Germany LI Liechtenstein SD Sudan DK Denmark LK Sri Lanka SE Sweden	CU	Cuba	ΚZ	Kazakstan	RO	Romania		
DK Denmark LK Sri Lanka SE Sweden	CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
	DE	Germany	LI	Liechtenstein	SD	Sudan		
EE Estonia LR Liberia SG Singapore	DK	Denmark	LK	Sri Lanka	SE	Sweden		
	EE	Estonia	LR	Liberia	SG	Singapore		

WO 00/34240 PCT/US99/27914

5

PROCESS FOR THE SYNTHESIS OF AZETIDINONES

Background

10 This

This invention relates to an enantioselective process for producing hydroxy-alkyl substituted azetidinones useful as hypocholesterolemic agents, in particular for preparing 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone, claimed in US 5,767,115.

15 Proce

Processes for preparing the corresponding azetidinone without the 3-hydroxy substitutent are claimed in US 5,728,827 and US 5,561,227. Other processes for preparing 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)-propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone are disclosed in US 5,631,365 and US 5,739,321.

20

Summary of the Invention

This invention provides an improved simple, high-yielding process using neutral conditions for producing the hypocholesterolemic azetidinone having the formula I

25

30

comprising:

(a) reacting p-fluorobenzoylbutyric acid of formula II with pivaloyl chloride and acylating the product with a chiral auxiliary of formula III to obtain a ketone of formula IV:

$$F \xrightarrow{OH} OH + X \xrightarrow{Cl} \frac{HN}{R^{\frac{1}{2}}} \xrightarrow{III} F \xrightarrow{IV} \frac{N}{R^{\frac{1}{2}}} X$$

15

20

wherein X is -O-, -S- or -N(C_1 - C_6 alkyl); Y is =O or =S; and R¹ is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl, phenyl and benzyl;

(b) reducing the ketone of formula IV in the presence of a chiral catalyst to an alcohol of formula V:

$$F \xrightarrow{O} \xrightarrow{O} \xrightarrow{N} X \xrightarrow{O} F \xrightarrow{O} \xrightarrow{N} X$$

(c) reacting the chiral alcohol of formula V, an imine of formula VI
 and a silyl protecting agent, then condensing the silyl-protected compounds to obtain a β-(substituted-amino)amide of formula VII, wherein Prot is a silyl protecting group:

$$F \xrightarrow{OH} \xrightarrow{OH} X \xrightarrow{N} X \xrightarrow{N} \xrightarrow{OH} X \xrightarrow{N} \xrightarrow{P} \xrightarrow{S} O(Prot)$$

- (d) cyclizing the β-(substituted-amino)amide of formula VII with
- (i) a silylating agent and a fluoride ion catalyst cyclizing agent;
 - (ii) a silylating agent and a quaternary ammonium salt of a chiral auxiliary of formula III; or
 - (iii) a strong non-nucleophlic base; to obtain the compound of formula VIII:

(e) removing the silyl protecting groups.

Also claimed are the process comprising steps (c), (d) and (e); the process of steps (d) and (e); the process of step (c); and the process of step (d), particularly the cyclization described in step (d)(i).

In still another aspect, the intermediates of formula VII and VIII are claimed.

The process described above is directed to the preparation of the 1-(4-fluorophenyl)-3(R)-[3(S)-hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4-hydroxyphenyl)-2-azetidinone enantiomer, but it will be recognized that by

substitution of the appropriate starting materials, other enantiomers can be prepared.

Detailed Description

The process of this invention is a high throughput process which provides the desired azetidinone in high overall yield in a short time cycle (i.e., about two weeks).

Preferred reaction conditions are shown in the following scheme: Step (a):

15 Step (b):

Step (c):

10

20

In the reaction scheme, TEA is triethylamine, DMAP is 4-dimethylamino pyridine, DIPEA is diisopropylethylamine, BSA is bistrimethylsilyl acetamide, TBAF is tetra n-butyl-ammonium fluoride, t-BuOMe is t-butyl methyl ether and Prot is a silyl protecting group as defined below.

Starting materials of formulas II and III are known in the art, and the procedure of step (a) for reacting compounds of formula II and III is known in the art: Preferably, the chiral auxiliary of formula III is exemplified by the formula:

wherein Y is =O, X is -O- and R^1 is phenyl, benzyl or C_1 - C_6 alkyl. A

15 See the example below for typical reaction conditions.

Similarly, the procedure of step (b) for reducing a ketone to a hydroxy group using a borane reducing agent such as BH₃• S(CH₃)₂ in the presence of a chiral catalyst such as (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo(1,2-c)(1,3,2) oxaza-borolidine is known: see U.S. 5,767,115.

10

15

20

25

30

35

In step (c), the chiral alcohol, V, and the imine, VI, are protected with a suitable hydroxy-protecting group, preferably a silyl protecting group such as that derived from chlorotrimethylsilane (TMSCI) or t-butyldimethyl-silyl chloride (TBDMSCI). The alcohol (1 equivalent) and imine (preferaby 1-3 equivalents) are added to an anhydrous solvent such as CH₂Cl₂, the reaction mixture is cooled to -10° to 15°C, a tertiary amine base such as DIPEA is added (preferably 2-4 equivalents), and sufficient silylating reagent to react with both the alcohol and the imine is added (e.g., 2-4 equivalents). After silylation is complete, the alcohol and imine are condensed by reacting at -20° to -35°C with at least 1 equivalent of a Lewis acid such as TiCl₄, in the presence of a tertiary amine base (preferably 1-3 equivalents) such as DIPEA for 2-4 hours. The reaction is quenched, for example by treating with an acid such as glacial acetic acid followed by aqueous tartaric acid solution; the resultant product is extracted and crystallized using conventional procedures.

Silylation in step (d) is effected by reacting the compound of formula VII with a silyl-enol ether silylating agent such as bistrimethylsilyl acetamide (BSA), N-methyl-O-trimethylsilyl acetamide or iso-propenyloxy trimethylsilane, preferably BSA, in a suitable inert organic solvent at -20°C to 110°C, preferably at about 0°C to 25°C. The reaction is preferably carried out in a dry, inert atmosphere, e.g., the solvent is dried, typically with molecular sieves, and the reaction is carried out under nitrogen.

The order of addition of the components of this process in Step (d) is not critical to the preparation of the azetidinone product. For example, the β -(substituted-amino)amide can first be reacted with the silylating agent and then reacted with the cyclizing agent, or the compound of formula VII can be added to a mixture of the silylating agent and the cyclizing agent. When the silylation and cyclization are done sequentially, i.e., the silylating agent is reacted with the starting material first, the silylation reaction can be allowed to continue for up to about two hours, but preferably the cyclization step is carried out immediately after silylation, or the silylating agent and the cyclizing agent are added simultaneously.

The source of the fluoride ion used to catalyze the intra-molecular cyclization of the compound of formula VII is typically a quaternary alkyl-, aryl-alkyl- or arylalkyl-alkylammonium fluoride salt or a hydrate thereof, or a mixture thereof, or is an alkali metal fluoride salt or a hydrate thereof, such as cesium fluoride or potassium fluoride. Examples of arylalkyl-

25

30

alkylammonium groups are benzyltriethyl-ammonium and benzyltrimethylammonium; examples of arylalkyl-ammonium are phenyltriethylammonium and phenyltrimethyl-ammonium; typical alkylammonium groups contain alkyl groups of 1-6 carbon atoms, e.g., tetra n-butyl-ammonium. 5 When a hydrated quaternary ammonium fluoride salt is used, the reagent is added in a catalytic amount, i.e., about 0.1 to about 20 mole percent, preferably about 0.5 to 5 mole percent, and when an anhydrous quaternary ammonium fluoride salt is used, it can be added in a catalytic up to a stoichiometric amount. When an alkali metal fluoride salt is used, it is 10 added in catalytic amount up to a stoichiometric amount compared to the starting β-amino compound, depending on the solubility of the reagent in the solvent used (higher solubility requires less reagent). If added to the reaction mixture after the silylation agent, the fluoride reagent is added directly to the reaction mixture resulting from silylation, and is reacted at 15 about 0°C to 110°C, preferably about 0°C to 50°C, for about 0.5 to about 6 hours, preferably about 2 hours. When the silylation reagent and the fluoride reagent are added simultaneously, the reaction is conducted under similar conditions. A preferred fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.

Alternatively, the cyclization of step (d) can be effected by the addition of a monovalent quaternary ammonium salt of the chiral auxiliary of formula III used in step (a), i.e., a compound of the formula

$$Z^+N$$
 X or HN X

wherein X, Yand R¹ are as defined above and Z is a quaternary ammonium cation selected from the group consisting of arylalkyl-alkylammonium, arylalkylammonium and tetraalkylammonium, or a mixture thereof, and alkali metals. Examples of arylalkyl-alkylammonium are benzyltriethylammonium and benzyl-trimethylammonium; examples of aryl-alkylammonium are phenyltriethylammonium and phenyltrimethyl-ammonium; typical tetraalkylammonium groups contain alkyl groups of 1-6 carbon atoms, e.g., tetra n-butylammonium; and typical alkali metals are sodium, potassium, cesium and lithium. Other chiral or non-chiral auxiliaries can also be used to cyclize the β -(substituted-amino)amide of formula VII, for example compounds of the formulas

10

15

20

25

30

$$Z^+N$$
 X or HN X

wherein X, Y, Z and R¹ are as defined above and R² is defined as for R¹ can also be used. The the β -(substituted-amino)amide of formula VII is treated with a silylating agent as described above, with the salt of the chiral (or non-chiral) auxiliary being added either simultaneously or sequentially in a catalytic or stoichiometric amount compared to the β -amino compound under conditions similar to the reaction with fluoride ion.

A third method for cyclizing the β -(substituted-amino)amide of formula VII comprises using a strong non-nucleophilic base. A strong non-nucleophilic base is defined herein as a non-aqueous base which does not act as a nucleopile by virtue of its steric bulk, e.g., sodium bistrimethylsilylamide or lithium diisopropylamide. The base is reacted with the the β -amino compound in an inert organic solvent such as CH_2Cl_2 at a temperature of about -100°C to 10 °C.

Removal of the protecting groups after cyclization is carried out using conventional methods, for example by treatment with a dilute acid such as sulfuric acid in a solvent such as an alcohol, e.g., isopropanol.

Intermediates IV and VII can be isolated during the reaction process, or the reaction can proceed to formation of the compound of formula I before the product is isolated.

The azetidinone resulting from the cyclization can be purified by appropriate standard procedures such as crystallization or column chromatography.

The term "suitable inert organic solvent" as used above means any organic solvent or combination of solvents that is unreactive in the reaction being conducted and is a solvent for the reactants. Typical suitable solvents are halogenated compounds such as CH₂Cl₂; heterocyclic compounds such as tetrahydrofuran (THF); DMSO; dimethylformamide (DMF); acetonitrile; carbocyclic aromatics such as toluene; and t-BuOMe. Preferred are t-BuOMe, CH₂Cl₂, toluene and THF.

Those skilled in the art will recognize that for cyclization of step (d) to proceed as desired, the -OH substituents present in the intermediates of formulas V and VI used in step (c) must be protected prior to cyclization, hence the treatment in step (c) with a hydroxy-protecting group. A key

feature of this process is the surprising stability of the silyl protecting groups on the carbinol and phenol moieties in both step (c) and step (d). In step (c), after the reaction of intermediates V and VI, the reaction is quenched with acid, preferably acetic acid and aqueous tartaric acid: the resulting solution has a pH <1. Under these conditions, one would not predict that the disilylated compound of formula VII (containing a silylated phenolic group) would be stable, but surprisingly the compound is stable and can be isolated for use in the next step of the process. Also, in step (d) of the process of the invention, out of the three silylated groups (i.e., the two hydroxy groups silylated in step (c) and the -NH- group silylated in the first part of step (d)), the -N-Si- group is selectively desilylated, allowing the intramolecular cyclization to proceed efficiently. This was unpredictable, especially in view of the presence of a silylated phenol group.

The following example illustrates the process of this invention.

15 Step (a):

5

10

20

25

Equip a 3-necked 500 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add p-fluoro-benzoylbutyric acid (20 g, 95.15 mmol), CH₂Cl₂ (100 mL) and TEA (23 mL, 165 mmol) and agitate the mixture at room temperature for 5 min. Add trimethylacetyl chloride (11.3 mL, 91.75 mmol) slowly over a period of 30 min. Check for complete formation of mixed anhydride by NMR.

Add the compound of formula III (10 g, 61.3 mmol), DMAP (1.6 g, 13 mmol) and dry DMF (10 mL) and heat the mixture at reflux for about 7 h or until the reaction is complete (<3% compound III) by NMR. Cool to room temperature, transfer the batch to a flask containing 2N $\rm H_2SO_4$ (80 mL) slowly with agitation and continue agitation for about 30 min. Separate the layers and wash the organic layer with 5% NaHCO₃ (80 mL)

Concentrate the organic layer and crystallize the product from isopropyl alcohol (100 mL), filter and dry. Yield: 20 g (92% molar); mp: 92-94°C.

Step (b):

5

10

15

20

25

Step (c):

Equip a 3-necked 250 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add dry CH₂Cl₂ (20 mL) and neat borane dimethyl sulfide (2.82 mL, 28.2 mmol) and cool the mixture to -5° to 0°C. Add a previously prepared toluene solution of (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo(1,2-c)(1,3,2) oxaza-borolidine (1.4 mL, 1.4 mmol, 5 mole %) to the mixture and stir for 15 min. at < 0°C. Add a solution of compound IV(10 g, 28.1 mmol) in CH₂Cl₂ (30 mL) slowly over a period of 3-4 h and maintain the reaction temperature between -5° to 0°C. Continue stirring for 1 to 2 h or until the reaction complete (<0.1% compound IV) by NMR. Quench the reaction by slowly adding CH₃OH (4 mL) while maintaining the temperature <0°C. Add 5% hydrogen peroxide (20 mL) followed by 4N H₂SO₄ (1.5 mL). Agitate the mixture for 15 min., separate the organic layer and wash with 2N H₂SO₄ (20 mL), 5% Na₂SO₃ (50 mL) and 10% NaCl (50 mL). Concentrate the organic layer to a low volume until water content is <0.05%. The product is used directly in

the next step. Solution yield: >95%; de: 98%.

Equip a 3-necked 500 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add the CH_2Cl_2 solution of compound V (10 g equivalent of compound IV, 28.1 mmol) from step (b) and compound VI (12.05 g) and adjust the total volume of the reaction

10

15

25

mixture to 150 mL with dry CH₂Cl₂. Cool the mixture to -10°C and add slowly DIPEA (25.7 mL, 147.5 mmol) and maintain the temperature at < -5°C. Add TMSCI (13.5 mL, 92.3 mmol) over a period of 30 min. while maintaining the reaction temperature <-5°C. Agitate the reaction for 1 h or until the silylation is judged complete by NMR. Lower the reaction temperature to -25 to -30°C. Add TiCl₄ (3.4 mL, 30.8 mmol) slowly and maintain the temperature <-25°C. Agitate the reaction for 3 h at <-25°C and check the reaction completion by NMR. Add glacial acetic acid (8 mL) slowly to the reaction mixture while maintaining the reaction temperature between -25 and -30°C. Pour the reaction mixture into 7% aqueous tartaric acid solution (140 mL) at 0°C, agitate for 1-2 h, and allow the temperature to gradually rise to room temperature. Add 20% aqueous NaHSO3 solution (50 mL) and continue agitation for another 2 h. Separate the organic layer and wash with water (120 mL). Concentrate the organic layer to a low volume and add bistrimethylsilyl acetamide (8.4 mL) and heat the mixture to reflux for 30 min. Concentrate the mixture to remove CH2Cl2 and crystallize the product from an ethyl acetate and heptane mixture, filter, wash and dry to give 13 g (65% molar yield from compound IV) of compound VII.

20 Step (d):

Equip a 3-necked 500 mL round bottom flask with a thermometer, an addition funnel and a nitrogen inlet. Add compound VII (50 g, 69.7 mmol), tetrabutylammonium fluoride trihydrate (0.1 g, 0.32 mmol), bistrimethyl acetamide (30 mL) and t-butylmethyl ether (500 mL). Stir the mixture at room temperature for 2 h or until the reaction is judged complete by NMR. Add glacial acetic acid (2.5 mL) and concentrate the reaction mixture to an oil under vacuum.

Step (e):

WO 00/34240

5

15

20

25

30

Add a premixed solution of isopropyl alcohol (250 mL) and 2N H_2SO_4 (25 mL) to the product of step (d) and agitate the mixture at room temperature for 1 h. Crystallize compound I from aqueous isopropyl alcohol. Filter the product and wash with dilute aqueous isopropyl alcohol followed by water until the pH of wash is <5. Dry the product at 60°C in a draft oven or under vacuum to give 26.14 g (91.5% molar yield) of compound I.

Starting materials for the claimed process are made by the following typical procedures.

10 <u>Preparation of 4-(4-fluorobenzoyl)butyric acid:</u>

Charge 250 g of anhydrous AlCl₃ (1.87 moles) to a 2 L 3-neck round bottom flask, add 300 mL fluorobenzene (307.5 g; 3.2 moles) and cool the mixture in an ice bath to 5°C. Add a hazy suspension of 100 g glutaric anhydride (0.86 mole) in 400 mL fluorobenzene (4.3 moles) through an addition funnel over a period of 45 min., and maintain the temperature below 12°C. Warm the reaction mixture to ambient temperature gradually and agitate at r.t. for about 90 min.; check for completion by NMR. Cool the reaction mixture to 0 to 5°C, then add a cold aqueous solution (700 mL) of 1N HCl carefully to the mixture to destroy any unreacted AICI₃, keeping the temperature of the mixture below 20°C during the early part of the acid addition, and below 40°C for the rest of the time. Pour the entire mixture into a 2 L 1:1 mixture of water and ice (v/w) to precipitate out crude products, filter the white suspension and wash well with water. Add the white residue to 3 L of aqueous saturated solution (~5%) of NaHCO₃, heat the basic mixture on a steam bath for one hour and filter the batch while hot through a thin pad of celite. Cool the filtrate to r.t., add about 320 mL of concentrated HCl dropwise into the filtrate to pH 1 to crystallize out products, and agitate the white suspension in an ice bath for 30 min. Filter the batch, wash the wet cake with ice cold water and dry in a vacuum oven at 50°C for 16 h to obtain 143.2 g of 4-(4-fluorobenzoyl)-butyric acid; m.p. 141 to 142°C, isolated yield: 79.3%.

Preparation of Imine:

10

$$_{\rm F}$$
 $_{\rm HO}$ $_{\rm HO}$ $_{\rm HO}$ $_{\rm HO}$ $_{\rm HO}$

Equip a three necked 1L flask with a mechanical stirrer, thermometer and an addition funnel. Add 480 mL of isopropanol, 144 g (1.18 moles) of p-hydroxybenzaldehyde (endothermic) and agitate the mixture while heating to a temperature of 50°C. Agitate the mixture at 50°C for 15 min (making sure all the material is in solution), then add 114 mL (1.2 moles) of p-fluoroaniline slowly via the addition funnel (exothermic reaction). After the addition is complete, agitate the thick slurry for 1hr at 50°C, cool to r.t. and agitate for 30 min. Filter the product, wash the cake with 150 mL of isopropanol, dry the wet cake in a draft oven at 50°C for 24 h or until dry to yield 222 g of the imine (88%); mp: 180-182°C

We claim:

1. A process for preparing a compound represented by the formula

5 comprising:

15

(a) reacting p-fluorobenzoylbutyric acid of formula II with pivaloyl chloride and acylating the product with a chiral auxiliary of formula III to obtain a ketone of formula IV:

$$F \xrightarrow{O} OH + X \xrightarrow{CI} \frac{HN}{R^{1}} \underbrace{III}_{IV} F \xrightarrow{IV} R^{1}$$

- wherein X is -O-, -S- or -N(C₁-C₆ alkyl); Y is =O or =S; and R¹ is C₁-C₆ alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C₁-C₆ alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C₁-C₆ alkyl, phenyl and benzyl;
 - (b) reducing the ketone of formula IV in the presence of a chiral catalyst to an alcohol of formula V:

$$F \xrightarrow{0} F \xrightarrow{0} F \xrightarrow{0} F$$

(c) reacting the chiral alcohol of formula V, an imine of formula VI and a silyl protecting agent, then condensing the silyl-protected
 compounds to obtain a β-(substituted-amino)amide of formula VII, wherein Prot is a silyl protecting group:

- (d) cyclizing the β -(substituted-amino)amide of formula VII with (i) a silylating agent and a fluoride ion catalyst cyclizing agent;
- (ii) a silylating agent and a quaternary ammonium salt of a chiral auxiliary of formula III; or
- (iii) a strong non-nucleophlic base; to obtain the compound of formula VIII:

- (e) removing the silyl protecting groups.
- 2. The process of claim 1 wherein in step (a), the chiral auxiliary is (4S)-4-phenyl-2-oxazolidinone; in step (b) the chiral catalyst is (R)-tetrahydro-1-methyl-3,3-diphenyl-1H,3H-pyrrolo(1,2-c)(1,3,2) oxazaborolidine; in step (c) the silyl protecting agent is chlorotrimethylsilane, the Lewis acid is $TiCl_4$ and the tertiary amine is diisopropylethylamine; and in step (d) the silylating agent is bistrimethylsilyl acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.
- A process for preparing a compound represented by the formula

5

10

15

comprising:

reacting a chiral alcohol of formula V, an imine of formula VI and a silyl protecting agent, then condensing the silyl-protected compounds to obtain a β -(substituted-amino)amide of formula VII, wherein X is -O-, -S- or

-N(C_1 - C_6 alkyl); Y is =O or =S; and R¹ is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl, phenyl and benzyl; and wherein Prot is a silyl protecting group:

cyclizing the β -(substituted-amino)amide of formula VII with a silylating agent and a fluoride ion catalyst cyclizing agent to obtain the compound of formula VIII:

removing the silyl protecting groups.

- 4. A process of claim 3 wherein the the silyl protecting agent is chlorotrimethylsilane; the condensation is effected with a Lewis acid in the presence of a tertiary amine; and the silylating agent is bistrimethylsilyl acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.
- 5. A process for preparing a compound represented by the formula

20

15

comprising cyclizing a β-(substituted-amino)amide of formula VII,

wherein X is -O-, -S- or -N(C_1 - C_6 alkyl); Y is =O or =S; and R¹ is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl, phenyl and benzyl; and wherein Prot is a silyl protecting group, with a silylating agent and a fluoride ion catalyst cyclizing agent to obtain the compound of formula VIII:

10

5

- (e) removing the silyl protecting groups.
- 6. A process of claim 5 wherein the silylating agent is bistrimethylsilyl acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.

15

20

7. A process for preparing a β-(substituted-amino)amide of the formula

wherein X is -O-, -S- or -N(C_1 - C_6 alkyl); Y is =O or =S; and R¹ is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl,

phenyl and benzyl; and wherein Prot is a silyl protecting group, comprising reacting a chiral alcohol of formula V.

an imine of formula VI

5

20

and a silyl protecting agent, then condensing the silyl-protected compounds to obtain the β -(substituted-amino)amide.

- 8. The process of claim 7 wherein the silyl protecting agent is
 10 chlorotrimethylsilane and the condensation is effected with a Lewis acid in the presence of a tertiary amine.
 - 9. A process for preparing a compound of the formula

wherein Prot is a silyl protecting group, comprising cyclizing a β (substituted-amino)amide of the formula

wherein X is -O-, -S- or -N(C_1 - C_6 alkyl); Y is =O or =S; and R¹ is C_1 - C_6 alkyl, phenyl, naphthyl, substituted phenyl, substituted naphthyl, C_1 - C_6 alkoxycarbonyl or benzyl, wherein the substituents on phenyl and naphthyl are 1-3 substituents selected from the group consisting of C_1 - C_6 alkyl,

phenyl and benzyl; and wherein Prot is as defined above, with a silylating agent and a fluoride ion catalyst cyclizing agent.

- 10. A process of claim 9 wherein the silylating agent is bistrimethylsilyl
 acetamide and the fluoride ion catalyst cyclizing agent is tetrabutylammonium fluoride trihydrate.
 - 11. A compound of the formula

- 10 wherein Prot is a silyl protecting group.
 - 12. A compound of the formula

wherein Prot is a silyl protecting group.

Internet. al Application No PCT/US 99/27914

			101/03 33/2/314
A CLASSI IPC 7	RCATION OF SUBJECT MATTER C07D205/08		
According to	International Patent Classification (IPC) or to both national classific	ation and IPC	
B. FIELDS			
Minimum do IPC 7	currentation searched (classification system followed by classification CO7D	ion symbols)	
	ion searched other than minimum documentation to the extent that		
	ata base consulted during the international search (name of data be	ase and, where practica	I, search terms used)
C' DOCUME	ENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the re	levant passages	Relevant to claim No.
Y	WO 97 16424 A (SCHERING CORPORAT 9 May 1997 (1997-05-09) the whole document	ION)	1
Y	US 5 767 115 A (STUART B. ROSENB AL.) 16 June 1998 (1998-06-16) cited in the application the whole document	LUM ET	1
Υ	US 5 739 321 A (GUANG-ZHONG WU E 14 April 1998 (1998-04-14) cited in the application the whole document	T AL.)	1
		-/	
l			1
X Furt	her documents are listed in the continuation of box C.	X Patent family	y members are listed in annex.
* Special ca	ategoriee of cited documents:	The factor document on	Allahad after the International Chardon
consid	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international	or priority date a cited to understa invention	blished after the international filing date not not in conflict with the application but and the principle or theory underlying the
filing o	tate	cannot be consid	cular relevance; the claimed invention fered novel or cannot be considered to tive step when the document is taken alone
which obstice	ent which may throw doubts on priority claim(s) or is dised to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"Y" document of participants of cannot be considered."	ave step when the document is taken alone dered to involve an inventive step when the abined with one or more other such docu-
other in	means ent published prior to the international filing date but han the priority date claimed	ments, such con in the art.	abination being obvious to a person skilled or of the same patent family
Date of the	actual completion of the international search	Date of maling of	of the International search report
4	April 2000	10/04/	2000
Name and I	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL – 2280 HV Rijewijk	Authorized office	•
	Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fexc (+31-70) 340-3016	Kyriak	akou, G

1

Interna. al Application No PCT/US 99/27914

US 5 728 827 A (TIRUVETTIPURAM KANNAPAN THIRUVENGADAM ET AL.) 17 March 1998 (1998-03-17) cited in the application the whole document US 5 561 227 A (TIRUVETTIPURAM K. THIRUVENGADAM ET AL.) 1 October 1996 (1996-10-01) cited in the application	Relevant to claim No.
US 5 728 827 A (TIRUVETTIPURAM KANNAPAN THIRUVENGADAM ET AL.) 17 March 1998 (1998-03-17) cited in the application the whole document US 5 561 227 A (TIRUVETTIPURAM K. THIRUVENGADAM ET AL.) 1 October 1996 (1996-10-01)	1
THIRUVENGADAM ET AL.) 17 March 1998 (1998-03-17) cited in the application the whole document US 5 561 227 A (TIRUVETTIPURAM K. THIRUVENGADAM ET AL.) 1 October 1996 (1996-10-01)	
THIRUVENGADAM ET AL.) 1 October 1996 (1996–10–01)	1
the whole document	
US 5 631 365 A (STUART B. ROSENBLUM ET AL.) 20 May 1997 (1997-05-20) cited in the application the whole document	
·	
	AL.) 20 May 1997 (1997—05-20) cited in the application

Information on patent family members

Internet. / Application No PCT/US 99/27914

Patent document cited in search report	•	Publication date		Patent family member(s)	Publication date
WO 9716424	A	09-05-1997	AU	7472896 A	22-05-1997
		3.5.	ÜS	5856473 A	05-01-1999
US 5767115	A	16-06-1998	US	5631365 A	20-05-1997
			US	5846966 A	08-12-1998
			AT	180249 T	15-06-1999
			AU	681445 B	28-08-1997
			AU	7795294 A	10-04-1995
			CN	1131416 A	18-09-1996 14-08-1996
			CZ De	9600839 A 69418613 D	24-06-1999
			DE	69418613 T	30-09-1999
			EP	0720599 A	10-07-1996
			ES	2132432 T	16-08-1999
			FI	961300 A	21-03-1996
			GR	3030312 T	30-09-1999
			HÜ	73852 A	30-09-1996
			JP	2803908 B	24-09-1998
			JP	8509989 T	22-10-1996
			KR	186853 B	01-05-1999
			NO	961133 A	20-03-1996
			NZ	274041 A	19-12-1997
			PL	313589 A	08-07-1996
			SG	46208 A	20-02-1998
			SK	35596 A	05-02-1997
			MO	9508532 A	30-03-1997
			ZA	9407086 A	14-03-1995
US 5739321	A	14-04-1998	AU	3299497 A	05-01-1998
			EP	0906278 A	07-04-1999
			JP WO	11511754 T 9745406 A	12-10-1999 04-12-1997
US 5728827	A	17-03-1998	AU Au	681419 B 7214694 A	28-08-1997 06-02-1995
			CA	2166784 A	19-01-1995
			CN	1126989 A	17-07-1996
			CZ	9600076 A	17-04-1996
			EP	0707567 A	24-04-1996
			FÏ	960095 A	09-01-1996
			HŪ	73237 A	29-07-1996
			JP	2840452 B	24-12-1998
			JP	8507085 T	30-07-1996
			KR	176001 B	20-03-1999
			MX	9405152 A	31-01-1995
			NO	960083 A	04-03-1996
			NZ	268798 A	29-01-1997
			PL	312502 A	29-04-1996
			SK	3796 A	05-02-1997
			MO	9501961 A	19-01-1995
US 5561227	A	01-10-1996	US	5306817 A	26-04-1994
			UA	658441 B	13-04-1995
			CZ	9400142 A	13-07-1994
			DE	69222532 D	06-11-1997
			DE	69222532 T	26-02-1998
			r n		
			EP FI	0596015 A 940296 A	11-05-1994 21-01-1994

information on patent family members

Internet. Application No PCT/US 99/27914

Patent document cited in search report		Publication date		atent family member(s)	Publication date
US 5561227	A		JP	6508637 T	29-09-1994
	••		NO	940221 A	21-01-1994
			SK	7994 A	06-07-1994
			ÜŜ	5688787 A	18-11-1997
			AT	158789 T	15-10-1997
•			AÜ	2398092 A	23-02-1993
			BG	61118 B	29-11-1996
			CA	2114007 A	04-02-1993
			CN	1069024 A	17-02-1993
			EP	0524595 A	27-01-1993
			ES	2107548 T	01-12-1997
			HU	67341 A	28-03-1995
			. JP	2525125 B	14-08-1996
			MX	9204327 A	29-07-1994
			NZ		
				243669 A 9878 A	22-12-1994
			OA UO		15-09-1994 04-02-1993
			MO	9302048 A ·	
			US Za	5688785 A	18-11-1994 31-03-1993
				9205487 A	21_02_1332
US 5631365	A	20-05-1997	AT	180249 T	15-06-1999
			AU	681445 B	28-08-1997
		*	AU	7795294 A	10-04-1995
			CN	1131416 A	18-09-1996
			CZ	9600839 A	14-08-1996
			DE	69418613 D	24-06-1999
			DE	69418613 T	30-09-1999
			EP	0720599 A	10-07-1996
			ES	2132432 T	16-08-1999
			FI	961300 A	21-03-1996
			GR	3030312 T	30-09-1999
			HU	73852 A	30-09-1996
			JP	2803908 B	24-09-1998
			JP	8509989 T	22-10-1996
			KR	186853 B	01-05-1999
			NO	961133 A	20-03-1996
			NZ	274041 A	19-12-1997
			PL	313589 A	08-07-1996
			SG	46208 A	20-02-1998
			SK	35596 A	05-02-1997
			WO	9508532 A	30-03-1995
			US	5767115 A	16-06-1998
			US	5846966 A	08-12-1998
		•	ZA	9407086 A	14-03-1999